Kevin MacDonald Quoted by LSIPR on Argentina’s Patent Reforms and Impact on Pharma Strategy
Kevin MacDonald was quoted by Life Sciences Intellectual Property Review (LSIPR) in an article titled “Argentina’s Patent Reset: Why Pharma Can No Longer Ignore Latin America's Second-Largest Market.” The article explores sweeping changes to Argentina’s IP regime, including the removal of restrictive pharmaceutical patent guidelines and broader reforms aimed at aligning the country with global standards.
Kevin noted that the new rules are not retroactive, describing a “safe harbor” that protects products already on the market prior to patent grants, which may limit enforcement and damages. He also highlighted the broader market impact, explaining that the reforms could incentivize innovator companies while creating “additional roadblocks for generics competition.”
He further observed that expanded patent eligibility may allow companies to pursue later-developed innovations, potentially “lengthen[ing] periods of exclusivity” and delaying generic entry. Kevin advised companies to reassess their patent strategies, including revisiting existing portfolios and monitoring how the changes are implemented in practice. Read more (subscription required).
Related content: